A Dicker1, M Rydén1, E Näslund2, I E Muehlen1, M Wirén3, M Lafontan4, P Arner5. 1. Department of Medicine, M61, Huddinge University Hospital, Karolinska Institute, 14186, Stockholm, Sweden. 2. Department of Surgery, Danderyd Hospital, Stockholm, Sweden. 3. Department of Surgery, Huddinge University Hospital, Karolinska Institute, Stockholm, Sweden. 4. INSERM, French National Institute for Health and Medical Research, Toulouse, France. 5. Department of Medicine, M61, Huddinge University Hospital, Karolinska Institute, 14186, Stockholm, Sweden. peter.arner@medhs.ki.se.
Abstract
AIM/HYPOTHESIS: Regional differences in lipolysis, with higher lipolytic activity in visceral than subcutaneous fat, are important for the development of insulin resistance and might be influenced by testosterone. METHODS: We studied testosterone-regulated lipolysis and protein expression (by western blot) in fully differentiated pre-adipocytes from visceral (omental) and abdominal subcutaneous adipose tissue from 52 human subjects. These cells were isolated and cultured in a serum-free medium. RESULTS: Testosterone caused a specific, time- and concentration-dependent 50% reduction of catecholamine-stimulated lipolysis in the subcutaneous depot. Half of the maximum effect occurred at 10 nmol/l. The inhibitory effect was due to the inability of beta-adrenoceptors and cyclic AMP to stimulate the protein kinase A, hormone-sensitive lipase complex. Testosterone caused a depot-specific 50% reduction of the protein expression of hormone-sensitive lipase and beta(2)-adrenoceptors in differentiated subcutaneous pre-adipocytes, but no change in beta(1)-adrenoceptors, protein kinase A subunits or perilipin expression. In contrast, testosterone had no effect on lipolysis or protein expression in the visceral depot. However, testosterone receptors were present in both depots, and the hormone inhibited adipocyte leptin secretion. Similar effects on lipolysis were observed with dihydrotestosterone. CONCLUSIONS/ INTERPRETATION: Testosterone in physiological concentrations causes a depot-specific reduction of catecholamine-stimulated lipolysis in subcutaneous fat cells, probably due to reduced protein expression of beta(2)-adrenoceptors and hormone-sensitive lipase. This could be an important pathogenic factor underlying regional differences in lipolysis and development of insulin resistance and hyperandrogenic polycystic ovary syndrome.
AIM/HYPOTHESIS: Regional differences in lipolysis, with higher lipolytic activity in visceral than subcutaneous fat, are important for the development of insulin resistance and might be influenced by testosterone. METHODS: We studied testosterone-regulated lipolysis and protein expression (by western blot) in fully differentiated pre-adipocytes from visceral (omental) and abdominal subcutaneous adipose tissue from 52 human subjects. These cells were isolated and cultured in a serum-free medium. RESULTS:Testosterone caused a specific, time- and concentration-dependent 50% reduction of catecholamine-stimulated lipolysis in the subcutaneous depot. Half of the maximum effect occurred at 10 nmol/l. The inhibitory effect was due to the inability of beta-adrenoceptors and cyclic AMP to stimulate the protein kinase A, hormone-sensitive lipase complex. Testosterone caused a depot-specific 50% reduction of the protein expression of hormone-sensitive lipase and beta(2)-adrenoceptors in differentiated subcutaneous pre-adipocytes, but no change in beta(1)-adrenoceptors, protein kinase A subunits or perilipin expression. In contrast, testosterone had no effect on lipolysis or protein expression in the visceral depot. However, testosterone receptors were present in both depots, and the hormone inhibited adipocyte leptin secretion. Similar effects on lipolysis were observed with dihydrotestosterone. CONCLUSIONS/ INTERPRETATION:Testosterone in physiological concentrations causes a depot-specific reduction of catecholamine-stimulated lipolysis in subcutaneous fat cells, probably due to reduced protein expression of beta(2)-adrenoceptors and hormone-sensitive lipase. This could be an important pathogenic factor underlying regional differences in lipolysis and development of insulin resistance and hyperandrogenic polycystic ovary syndrome.
Authors: M Wabitsch; W F Blum; R Muche; M Braun; F Hube; W Rascher; E Heinze; W Teller; H Hauner Journal: J Clin Invest Date: 1997-08-15 Impact factor: 14.808
Authors: Mikael Rydén; Andrea Dicker; Cecilia Götherström; Gaby Aström; Charlotte Tammik; Peter Arner; Katarina Le Blanc Journal: Biochem Biophys Res Commun Date: 2003-11-14 Impact factor: 3.575
Authors: Michelle R Jones; Gregorio Chazenbalk; Ning Xu; Angela K Chua; Tamar Eigler; Emebet Mengesha; Yen-Hao Chen; Jung-Min Lee; Marita Pall; Xiaohui Li; Yii-Der I Chen; Kent D Taylor; Ruchi Mathur; Ronald M Krauss; Jerome I Rotter; Richard S Legro; Ricardo Azziz; Mark O Goodarzi Journal: J Clin Endocrinol Metab Date: 2012-06-21 Impact factor: 5.958
Authors: Samantha C Fisch; Ariella Farzan Nikou; Elizabeth A Wright; Julia D Phan; Karen L Leung; Tristan R Grogan; David H Abbott; Gregorio D Chazenbalk; Daniel A Dumesic Journal: Fertil Steril Date: 2018-12 Impact factor: 7.329
Authors: Christina Koutsari; Asem H Ali; K Sreekumaran Nair; Robert A Rizza; Peter O'Brien; Sundeep Khosla; Michael D Jensen Journal: J Clin Endocrinol Metab Date: 2009-06-30 Impact factor: 5.958
Authors: Jeffrey D Covington; Sudip Bajpeyi; Cedric Moro; Yourka D Tchoukalova; Philip J Ebenezer; David H Burk; Eric Ravussin; Leanne M Redman Journal: Eur J Endocrinol Date: 2014-10-23 Impact factor: 6.664
Authors: Daniel A Dumesic; Luis R Hoyos; Gregorio D Chazenbalk; Rajanigandha Naik; Vasantha Padmanabhan; David H Abbott Journal: Reproduction Date: 2020-01 Impact factor: 3.906